Evidence map›Paper›PMID 19365593›Full record

ArticleEuropean journal of nutrition2009

Probiotic properties of Lactobacillus rhamnosus and Lactobacillus paracasei isolated from human faeces.

Maria Cristina Verdenelli, Francesca Ghelfi, Stefania Silvi, Carla Orpianesi, Cinzia Cecchini, Alberto Cresci

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05358301 (Novel Strategies for Obesity Prevention and Management With the Probiotic Lactiplantibacillus Plantarum IMC 510), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05358301 nacompletednot on this mapstarted 2022, after this paper: background citation

Novel Strategies for Obesity Prevention and Management With the Probiotic Lactiplantibacillus Plantarum IMC 510 (PRO-Weight-Control Study)

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria CareggiRan2022 to 2022Enrolled40ConditionsObesityArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Effects ofFrontiers in veterinary science · 2025
    Article
  10. The living medicine inside us:Gut microbes reports · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. ExploringAntibiotics (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. SYNBIOMicroorganisms · 2023
    Article
  19. Six-Month SynbioMicroorganisms · 2023
    Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Maria Cristina VerdenelliDipartimento di Scienze Morfologiche e Biochimiche Comparate, Università di Camerino, Camerino, Italy.
Francesca Ghelfi
Stefania Silvi
Carla Orpianesi
Cinzia Cecchini
Alberto Cresci
Università di Camerino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe possibility of using microbes to maintain health, and to prevent or treat disease is a topic as old as microbiology. The research of novel probiotic strains is important in order to satisfy the increasing request of the market and to obtain functional products in which the probiotic cultures are more active and with better probiotic characteristics than those already present on the market. AIM OF THE STUDY: In this study, the probiotic potential of Lactobacillus strains isolated from Italian elderly human faeces was investigated.

methodsThe Lactobacillus strains were identified and examined for resistance to gastric acidity and bile toxicity, adhesion to HT-29 cells, antimicrobial activities, antibiotic susceptibility and plasmid profile. Survival of the strains through human intestine was examined in a 3 months human feeding trial.

resultsTwo strains, Lactobacillus rhamnosus IMC 501 and Lactobacillus paracasei IMC 502, tolerated well low pH and bile acids. In antimicrobial activity assays, both strains showed inhibitory properties towards selected potential harmful microorganisms, particularly against Candida albicans. The two selected strains expressed high in vitro adherence to HT-29 cells increasing this characteristic when they are used in combination and they were resistant to vamcomycin, colistin sulphate, gentamicin, oxolinic acid and kanamycin. Moreover, the two strains could be recovered from stools of volunteers after the feeding trials.

conclusionsLactobacillus rhamnosus IMC 501 and L. paracasei IMC 502 present favourable strain-specific properties for their utilisation as probiotics in functional foods and the high adhesion ability of the L. rhamnosus IMC 501 and L. paracasei IMC 502 used in combination, confirmed by both in vitro and in vivo study, indicate that the two bacterial strains could be used as health-promoting bacteria.

Indexed as

ProbioticsAdultAgedAged, 80 and overAnti-Bacterial AgentsAntibiosisBacterial AdhesionBile Acids and SaltsCell LineEpithelial CellsFecesFemaleHumansHydrogen-Ion ConcentrationIntestinal MucosaLacticaseibacillus rhamnosusAnti-Bacterial AgentsBile Acids and SaltsRNA, Ribosomal, 16S

Identifiers

PMID19365593
OpenAlexW2140817425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.